Skip to main content
Biocorp logo

Biocorp — Investor Relations & Filings

Ticker · ALCOR ISIN · FR0012788065 LEI · 969500TKUAME6031UQ32 PA Manufacturing
Open in API
Filings indexed 235 across all filing types
Latest filing 2019-09-09 Report Publication Anno…
Country FR France
Listing PA ALCOR

About Biocorp

https://biocorpsys.com

Biocorp designs, develops, and manufactures medical devices and drug delivery systems for the pharmaceutical industry. The company specializes in combining precision engineering with connected technologies to improve patient treatment adherence and outcomes. Its portfolio includes both connected and non-connected devices, such as smart caps for inhalers (Inspair), pen injectors, and systems for drug reconstitution and safety. Biocorp manages the entire value chain, from research and development to manufacturing and final packaging, leveraging its expertise in plastics processing and advanced technological innovation. Since October 2023, Biocorp has been a subsidiary of Novo Nordisk.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Report Publication Announcement Classification · 1% confidence The document is a press release titled "BIOCORP announces its participation in several upcoming events by the end of the year." It details scheduled exhibitions (PODD, PDA, CPhI Worldwide) and investor meetings (Biotech Agora, Large & MidCap Event) where the company will present or unveil new products. This type of announcement, detailing future corporate activities aimed at investors and partners, is best classified as an Investor Presentation (IP) if it were the presentation itself, or more accurately, a general corporate update related to investor relations and market presence. Since it is an announcement *about* upcoming events and presentations, and not a formal regulatory filing like 10-K or a specific financial release like ER, it fits best under the general category of investor communication. Given the options, while it is an announcement, it is specifically about events where investor engagement is key. However, looking closely at the definitions, none perfectly capture an 'Upcoming Events Schedule' press release. It is not a formal Investor Presentation (IP) as it is just a schedule. It is not an Earnings Release (ER). It is not a Report Publication Announcement (RPA) because it is not announcing the publication of a formal report. It is a general corporate communication detailing future investor/industry engagement. The closest fit among the specific categories that deal with investor engagement and corporate activity announcements, but isn't a formal report, is often categorized under general investor relations material. Given the choices, and recognizing this is a forward-looking communication about market presence and investor meetings, it is most closely related to investor engagement materials. Since it is a press release announcing future activities, and not a specific financial report or regulatory filing, it falls into the general category of investor/corporate news. In many databases, such announcements default to a general regulatory/corporate filing category if a more specific one isn't available. However, since it is explicitly about events and meetings, it is a form of investor communication. If we must choose from the list, and recognizing it is a press release announcing future engagement, it is not a standard financial report. It is a general corporate announcement. The most appropriate general category for non-standard corporate announcements is RNS, but since it is heavily focused on investor/partner events, it shares characteristics with IP or ER announcements. Given the content is purely about future participation in industry events and investor meetings, it is a form of corporate communication aimed at the market. Since it is not a formal report or a specific financial event announcement, RNS (Regulatory Filings - general fallback) is a possibility, but let's re-evaluate if any other category fits the 'announcement' nature. It is not a DIV, DIRS, or SHA. It is not a CT. It is a press release announcing future corporate activities. In the absence of a specific 'Corporate Event Announcement' code, and given its focus on market presence and investor meetings, it is a general corporate update. I will classify this as a general Regulatory Filing (RNS) as it is a press release announcing corporate activity that doesn't fit the specific financial report codes, adhering to the fallback rule if a better fit is missing.
2019-09-09 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated September 9, 2019, announcing BIOCORP's schedule for participating in various professional trade shows and investor meetings between October and November 2019. It details specific events (PODD, PDA, CPhI Worldwide, Biotech Agora, Large & MidCap Event) where the company will present or unveil new products. This type of announcement, which informs the market about future corporate activities, presentations, and investor outreach, does not fit the specific definitions for financial reports (10-K, IR, ER), capital changes (CAP, SHA), or governance documents (DEF 14A, CGR). Since it is a general corporate announcement detailing future events and investor engagement, it is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were the presentation itself. Given that this is an announcement *about* attending events, RNS serves as the most appropriate general regulatory announcement category for non-standard disclosures.
2019-09-09 French
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Publication du nombre d'actions composant le capital social et du nombre total de droits de vote" (Publication of the number of shares comprising the share capital and the total number of voting rights). It explicitly references the French Commercial Code (Article L.233-8 II) and the AMF General Regulation (Article 223-16). The core content is a table showing the total number of shares and voting rights as of a specific date (June 30, 2019). This type of mandatory disclosure regarding the total share capital and voting rights is a specific regulatory filing related to capital structure changes or mandatory periodic updates. While it relates to shares, it is not a general share issue announcement (SHA) or a buyback (POS). It is a specific regulatory disclosure about the capital base. Given the options, this fits best under a general regulatory filing category, but since there is a specific category for 'Share Issue/Capital Change' (SHA), I must evaluate if this disclosure fits there. However, this is a periodic statement of the *current* capital base, not an announcement of a *change* (like an issuance or split). Since it is a formal, periodic regulatory disclosure that doesn't fit other specific financial reports (10-K, IR, ER), the most appropriate general regulatory category is RNS, or potentially SHA if interpreted broadly as capital structure reporting. Given the highly specific nature of the data (total shares/votes), and the reference to AMF regulations, it is a mandatory regulatory filing. Since there isn't a perfect fit for 'Total Share Capital Disclosure', RNS (Regulatory Filings) serves as the best general regulatory category for mandatory, non-standard report announcements. However, looking closely at the definitions, 'SHA' is for 'Share Issue/Capital Change'. This document reports the *status* of the capital, which is often required following capital changes or periodically. Given the context of French regulatory filings, this is often grouped with capital structure updates. Let's re-evaluate the options. It is not an ER, IR, 10-K, or CT. It is a formal regulatory notice. If we consider the closest fit among the specific codes, 'SHA' (Share Issue/Capital Change) is related to capital structure. However, the document is a simple statement of the current count, not an announcement of a change event. Therefore, RNS (Regulatory Filings) is the safest fallback for a specific regulatory disclosure that doesn't match the primary report types. The document length is short (2655 chars), suggesting it's an announcement rather than a full report, supporting RNS or RPA. Since it's a direct regulatory disclosure, RNS is preferred over RPA (which is for announcing the publication of *other* reports). I will classify it as RNS.
2019-07-09 French
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Capital/Financing Update Classification · 1% confidence The document is titled "Bilan semestriel du contrat de liquidité BIOCORP confié à la société Kepler Cheuvreux" (Semi-annual balance sheet of the BIOCORP liquidity contract entrusted to Kepler Cheuvreux). It details the status of a liquidity contract (actions and cash held) as of June 30, 2019, and the transactions executed during the first half of 2019 (January 1 to June 30). This type of filing, which reports on the status of a specific financial arrangement (liquidity contract/market making) on a periodic basis (semi-annually), does not fit neatly into the primary categories like 10-K, ER, or IR. It is a specific financial disclosure related to market operations. Since it is a specific regulatory/contractual update that doesn't match the defined codes (like DIV, CAP, or DIRS), the most appropriate fallback category is Regulatory Filings (RNS), as it is a required disclosure concerning market stability/liquidity management, or potentially a specialized financial update. Given the options, RNS serves as the best general regulatory disclosure category for non-standard periodic financial updates.
2019-07-09 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document announces an exclusive negotiation between BIOCORP and SANOFI regarding the Mallya connected device and an upfront payment of 4 M€. This is a significant business development and partnership announcement. It is not a standard periodic financial report (10-K, IR, ER), a formal shareholder vote result (DVA), or a management change (MANG). It relates to a strategic business agreement and potential future revenue/financing, but it is not explicitly a capital raise (CAP) or a takeover (TAR). Given the nature of announcing a major strategic deal and associated payment, it best fits under general corporate announcements. Since there isn't a specific code for 'Strategic Partnership Announcement,' and it is a material event announcement, the most appropriate general category among the provided options is 'Regulatory Filings' (RNS) as a catch-all for significant, non-standard corporate news, although 'CAP' (Capital/Financing Update) could be considered due to the upfront payment, 'RNS' is safer for general material news that isn't strictly financing or earnings related. However, upon re-evaluation, this is a material corporate event announcement, often released via press release. Since 'RNS' is the fallback for miscellaneous filings, and this is a press release announcing a major business development, RNS is the best fit among the limited options.
2019-07-03 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document announces that BIOCORP has entered into exclusive negotiations with SANOFI regarding the use of its connected device MallyaTM for diabetes treatment, including receiving an upfront payment of 4 M€. This is a significant corporate event related to a potential partnership, licensing, or acquisition activity. It is not a standard periodic financial report (10-K, IR, ER, MRQ), nor is it a management discussion (MDA) or an investor presentation (IP). It strongly aligns with an announcement regarding a major transaction or strategic development, which falls under Merger & Acquisition Activity (TAR) or potentially Capital/Financing Update (CAP) due to the upfront payment. Given the context of 'négociations exclusives' for integrating a technology into a partner's platform, it is best classified as M&A Activity (TAR), as these negotiations often lead to licensing or acquisition deals. Since the document is a press release detailing a strategic business development rather than a formal regulatory filing like a 10-K or a general regulatory notice (RNS), TAR is the most specific fit for a major strategic transaction announcement.
2019-07-03 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.